Clinical trials
Systemic Lupus Erythematosus clinical trials
Below are recruiting systemic lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06737380RecruitingPhase 1
Stem Cell Therapy Study for Active Lupus
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Charleston, South CarolinaAges 18–75 - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06676631RecruitingPhase 1
NK cells plus rituximab for active lupus
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
Guangzhou, GuangdomgAges 18–65 - NCT06625671RecruitingPhase 1/Phase 2
DB-2304 antibody injection for lupus skin disease (SLE/CLE)
This trial tests an experimental antibody injection (DB-2304) to see if it can improve lupus skin rashes and other lupus symptoms. It is for people with active lupus skin disease who have already tried standard treatments.
La Palma, CaliforniaAges 18–70 - NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Avondale, ArizonaAges 16 years+ - NCT06613360RecruitingPhase 1
Study of CLN-978 for people with systemic lupus erythematosus
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
Avondale, ArizonaAges 18–70 - NCT06585514RecruitingPhase 1/Phase 2
CAR T-cell therapy for hard-to-treat lupus
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Beijing, Beijing MunicipalityAges 3–65 - NCT06576271RecruitingPhase 1
Testing a new drug for lupus and related lung disease
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
Scottsdale, ArizonaAges 18–65 - NCT06551389Recruiting
Lupus follow-up study at Brest Hospital
This study follows people with systemic lupus erythematosus (an autoimmune disease) who are seen in a special clinic. It aims to track their health over time.
BrestAges 18 years+ - NCT06535412RecruitingPhase 1/Phase 2
Study of IMC-002 for active lupus
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
BeijingAges 18–65 - NCT05698173Recruiting
Study of lupus and accelerated aging
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
BordeauxAges 18–60 - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06475742Enrolling by invitationPhase 3
Long-term safety of cenerimod in lupus patients
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Aurora, ColoradoAges 18–75 - NCT06458075Recruiting
Improving communication and medication adherence in lupus
This study tests whether helping lupus patients and their doctors communicate better leads to taking medications more consistently. Participants will have their doctor visits recorded and use a phone app to track their medicines.
Durham, North CarolinaAges 18–90 - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT06400537RecruitingPhase 1
A-319 for active or tough-to-treat lupus (SLE)
This study tests a new drug called A-319 for people whose lupus (SLE) is active or hasn't improved with current treatments. The goal is to see if A-319 can help control lupus better.
Wuhan, HubeiAges 18–60 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06308770Recruiting
Online group program for lupus fatigue
This trial tests a new online group program to help people with lupus manage chronic fatigue. Participants are randomly assigned to either the program or standard care, and all complete questionnaires online.
EdinburghAges 18–85 - NCT06232304Recruiting
Program for young people with childhood lupus
This study tests a program to help teenagers and young adults with childhood-onset lupus manage symptoms like fatigue, sadness, or pain. It aims to improve daily life and well-being.
Birmingham, AlabamaAges 12–22 - NCT06133972RecruitingPhase 3
Long-term safety of ianalumab for lupus (extension study)
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Anniston, AlabamaAges 12–100 - NCT05029336RecruitingPhase 2
Stem cell transplant using your own cells for autoimmune disease
This Phase 2 study tests an autologous stem cell transplant (a treatment using your own blood-forming stem cells) for severe systemic sclerosis or severe lupus. The goal is to reset the immune system to help control the autoimmune disease.
Philadelphia, PennsylvaniaAges 8–25
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic lupus erythematosus?
- Yes. Clin2 currently lists 260 recruiting systemic lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.